A traditional Chinese medicine compound preparation for treating oviduct inflammation of laying hens and a preparation method thereof

Abstract

This invention provides a traditional Chinese medicine compound preparation for treating oviductitis in laying hens and its preparation method, belonging to the field of traditional Chinese veterinary medicine technology. Based on the principles of syndrome differentiation and treatment in traditional Chinese veterinary medicine, this invention rationally combines a traditional Chinese medicine compound preparation composed of Leonurus japonicus, Citrus aurantium, Euphorbia humifusa, Morus alba, Bombyx mori, Gynostemma pentaphyllum, Sophora flavescens, Solanum lyratum, Schisandra chinensis, and Glycyrrhiza uralensis. This compound preparation has the effects of clearing heat and dampness, promoting blood circulation and removing blood stasis, nourishing yin and replenishing qi, and strengthening the spleen and kidneys. This traditional Chinese medicine compound preparation can exert a significant anti-inflammatory effect by regulating the level of cellular inflammatory factors, and can enhance the body's immune function by regulating the level of immune proteins. Therefore, it can improve the egg production rate of laying hens affected by oviductitis, and reduce the mortality and defective egg rate caused by oviductitis. This traditional Chinese medicine compound preparation has great application prospects in the treatment of oviductitis in laying hens.

Description

Technical Field

[0001] This invention relates to the field of traditional Chinese veterinary medicine technology, specifically to a traditional Chinese medicine compound preparation for treating oviductitis in laying hens and its preparation method. Background Technology

[0002] Oviductitis in laying hens is a key disease hindering the healthy development of the laying hen industry, exhibiting high incidence and outbreaks, especially during peak and later laying periods. Epidemiological surveys show that approximately 20% of laying hen deaths are directly related to this disease. This disease leads to a significant decrease in egg production, an increase in abnormal eggs, and a higher mortality rate, causing substantial economic damage to the laying hen industry. The pathogenic factors of oviductitis in laying hens are complex, mainly involving pathogenic microorganism infection, nutritional imbalance, and improper feeding management. These factors work together to cause edema, mucosal damage, and inflammatory reactions in the oviduct tissue, thereby affecting eggshell formation and follicle health. In severe cases, it can induce yolk peritonitis, cloacitis, and other exacerbating production losses. With the implementation of the national "antibiotic reduction and ban" campaign, there is an urgent need to find a safe, efficient, residue-free, and non-resistant natural green antibiotic alternative to increase the antioxidant and anti-inflammatory capabilities of laying hens, ensure oviduct health, thereby improving laying hen production performance and protecting the economic benefits for farmers. Traditional Chinese medicine (TCM) has demonstrated unique value and broad application prospects in the prevention and treatment of oviductitis in laying hens due to its significant advantages, including natural sources, multi-target effects, low incidence of drug resistance, and low drug residues. This invention aims to provide a highly effective and safe TCM compound preparation for treating oviductitis in laying hens, along with its preparation method, offering a new treatment option for this condition. Summary of the Invention

[0003] (a) Technical problems to be solved

[0004] To address the shortcomings of existing technologies, this invention provides a traditional Chinese medicine compound preparation for treating oviductitis in laying hens and its preparation method.

[0005] (II) Technical Solution

[0006] To achieve the above objectives, the present invention provides the following technical solution:

[0007] First, the present invention provides a traditional Chinese medicine compound preparation for treating oviductitis in laying hens, the traditional Chinese medicine compound preparation being made from the following traditional Chinese medicinal materials in parts by weight: 10-30 parts of Leonurus japonicus, 20-40 parts of Citrus aurantium, 10-30 parts of Euphorbia humifusa, 10-30 parts of Morus alba, 10-30 parts of Coix lacryma-jobi, 10-30 parts of Gynostemma pentaphyllum, 10-30 parts of Sophora flavescens, 10-30 parts of Solanum lyratum, 10-30 parts of Schisandra chinensis, and 5-20 parts of Glycyrrhiza uralensis.

[0008] Preferably, the traditional Chinese medicine compound preparation is made from the following traditional Chinese medicinal materials in parts by weight: 10-20 parts of Leonurus japonicus, 25-35 parts of Citrus aurantium, 15-25 parts of Euphorbia humifusa, 10-20 parts of Morus alba, 15-25 parts of Eupatorium fortunei, 15-25 parts of Gynostemma pentaphyllum, 10-20 parts of Sophora flavescens, 15-25 parts of Solanum lyratum, 10-20 parts of Schisandra chinensis, and 5-15 parts of Glycyrrhiza uralensis.

[0009] Preferably, the traditional Chinese medicine compound preparation is made from the following traditional Chinese medicinal materials in parts by weight: 16 parts of Leonurus japonicus, 32 parts of Citrus aurantium, 22 parts of Euphorbia humifusa, 18 parts of Morus alba, 20 parts of Coix lacryma-jobi, 22 parts of Gynostemma pentaphyllum, 14 parts of Sophora flavescens, 21 parts of Solanum lyratum, 18 parts of Schisandra chinensis, and 9 parts of Glycyrrhiza uralensis.

[0010] Secondly, the present invention also provides a traditional Chinese medicine compound preparation for treating oviductitis in laying hens. The preparation method of the traditional Chinese medicine compound preparation is as follows: weigh each traditional Chinese medicine raw material according to the above-mentioned weight parts, wash and dry it, perform pulverization pretreatment, and then put the pretreated medicinal materials into an ultra-micro pulverizer for pulverization to 60-75μm. After mixing evenly, the traditional Chinese medicine compound preparation is obtained.

[0011] Furthermore, the traditional Chinese medicine compound preparation for treating oviductitis in laying hens provided by the present invention can also be prepared into oral liquid, granules, or powders by using the above-mentioned weight proportions of traditional Chinese medicinal materials as raw materials and supplementing them with pharmaceutically acceptable excipients.

[0012] Motherwort: The fresh or dried aerial parts of Leonurus japonicus Houtt., a plant in the Lamiaceae family. It is bitter, pungent, and slightly cold in nature; it enters the liver, pericardium, and bladder meridians; it has the effects of promoting blood circulation and regulating menstruation, promoting diuresis and reducing swelling, and clearing heat and detoxifying. It is used for irregular menstruation, dysmenorrhea, amenorrhea, lochia retention, edema with scanty urine, and carbuncles and boils.

[0013] Chiyangzi: The dried, mature fruit of Pyracantha fortuneana, a plant in the Rosaceae family; it is sweet and sour in taste and neutral in nature, and enters the liver meridian. It has the effects of strengthening the spleen and eliminating food stagnation, promoting blood circulation and stopping bleeding. It is mainly used to treat food stagnation, abdominal masses, diarrhea and dysentery, metrorrhagia and postpartum blood stasis.

[0014] Euphorbia humifusa Willd. ex Schltdl., a plant in the Euphorbiaceae family, is the dried whole herb, also known as "Blood-Seeing Sorrow" or "Spreading Ground Euphorbia". It is neutral in nature, pungent and bitter in taste, and enters the liver and large intestine meridians. It has the effects of clearing heat and detoxifying, cooling blood and stopping bleeding, and promoting diuresis and relieving jaundice. It is often used to treat dysentery, hematochezia, damp-heat jaundice, and external bleeding.

[0015] Mulberry: It is the dried fruit spike of the mulberry plant Mori Fructus. It is sweet, sour and cold in nature, and enters the heart, liver and kidney meridians. Its main functions are to nourish yin and blood, generate fluids and moisten dryness. It is used for liver and kidney deficiency, deficiency of essence and blood, dizziness and blurred vision, tinnitus and insomnia, premature graying of hair, etc.

[0016] Water cotton: The root of *Anemone hupehensis* Lem.F.alba WTWang, a plant in the Ranunculaceae family. It tastes bitter and astringent, and is cold in nature; it enters the stomach and liver meridians; it has the effects of clearing heat and dampness, promoting blood circulation and removing blood stasis. It is used for dysentery, gonorrhea, and rheumatic joint pain.

[0017] Ganhuangcao: The whole herb of Penthorum chinense Pursh, a plant of the genus Penthorum in the family Saxifragaceae; sweet and warm in nature; enters the liver and kidney meridians; has the effects of promoting diuresis and removing dampness, removing blood stasis and relieving pain, and is used for jaundice, edema, traumatic injuries, swelling and pain.

[0018] Lespedeza tomentosa (Thunb.) Sieb. ex Maxim., a plant belonging to the genus Lespedeza in the legume family, has a sweet and bland taste and is neutral in nature. It enters the spleen meridian and has the effects of strengthening the spleen and replenishing qi, clearing heat and promoting diuresis, and invigorating blood circulation and regulating menstruation. It is mainly used to treat general weakness, dizziness due to blood deficiency, edema, ascites, dysentery, amenorrhea, dysmenorrhea, and can also be used for hemorrhoidal bleeding.

[0019] Solanum lyratum: The dried whole herb of Solanum lyratum, a plant of the Solanaceae family, is cold in nature and bitter in taste. It enters the liver and gallbladder meridians and has the effects of clearing heat and detoxifying, promoting diuresis and reducing swelling, dispelling wind and relieving pain. It is widely used for sores, carbuncles and boils, damp-heat jaundice and rheumatic pain.

[0020] Schisandra chinensis: The dried, ripe fruit of Schisandra chinensis (Turcz.) Baill., a plant in the Magnoliaceae family; it has a sour and sweet taste, and is warm in nature; it enters the lung, heart, and kidney meridians; it has the effects of astringing and consolidating, replenishing qi and promoting body fluids, tonifying the kidneys and calming the mind. It is commonly used for chronic cough and wheezing, nocturnal emission and spermatorrhea, enuresis and frequent urination, chronic diarrhea, spontaneous sweating and night sweats, thirst due to fluid depletion, internal heat and thirst, palpitations and insomnia.

[0021] Licorice: The dried root and rhizome of *Glycyrrhiza uralensis* Fisch., *Glycyrrhiza inflata* Bat., or *Glycyrrhiza glabra* L. (all belonging to the Fabaceae family). It has a sweet taste and neutral properties, and enters the heart, spleen, lung, and stomach meridians. It has the effects of tonifying the spleen and replenishing qi, clearing heat and detoxifying, resolving phlegm and relieving cough, relieving spasms and pain, and harmonizing other herbs. It is used for symptoms such as spleen and stomach weakness, fatigue, palpitations, shortness of breath, cough with excessive phlegm, carbuncles, and boils. Licorice is also good at harmonizing the properties of other herbs and mitigating their toxicity.

[0022] (III) Beneficial Effects

[0023] This invention, based on the principles of traditional Chinese veterinary medicine, rationally combines a traditional Chinese medicine compound preparation consisting of Leonurus japonicus, Citrus reticulatae, Euphorbia humifusa, Morus alba, Bombyx mori, Gynostemma pentaphyllum, Sophora flavescens, Solanum lyratum, Schisandra chinensis, and Glycyrrhiza uralensis. In this compound preparation, Citrus reticulatae is the principal herb, known for its ability to invigorate blood circulation, remove blood stasis, clear heat, and resolve dampness. It can clear accumulated damp-heat and improve blood stasis in the oviduct, thus targeting the core pathogenesis of damp-heat stagnation in oviductitis in laying hens. Gynostemma pentaphyllum clears heat, promotes diuresis, and reduces swelling; Euphorbia humifusa cools the blood and disperses blood stasis; Solanum lyratum clears heat, detoxifies, promotes diuresis, and reduces swelling; Bombyx mori clears heat, promotes diuresis, invigorates blood, and removes blood stasis. These four herbs act as assistant herbs, enhancing the principal herb's ability to clear heat, promote diuresis, invigorate blood, and remove blood stasis. Furthermore, all four herbs are mild and gentle, eliminating pathogens without harming the body's vital energy. Motherwort excels at promoting blood circulation, regulating menstruation, and reducing swelling. It assists the principal and assistant herbs in clearing the uterine vessels and dispersing blood stasis, while also enhancing the effect of clearing damp-heat. Mulberry nourishes yin and blood, generates fluids and moistens dryness, and counteracts coldness. Sophora flavescens strengthens the spleen, eliminates dampness, and replenishes qi to aid blood circulation. Schisandra chinensis astringes and consolidates, replenishes qi and generates fluids, tonifies the kidneys and calms the mind, and has a warming effect. The four herbs work together to assist in eliminating pathogenic factors and stagnating blood, while also counteracting the deficiency of the principal and assistant herbs and preventing dryness and yin deficiency. Finally, licorice root acts as the guiding herb, harmonizing the effects of the herbs, replenishing qi and strengthening the middle jiao, and guiding the medicine to the affected area. It balances the cold and hot properties of the herbs, strengthens the spleen and stomach, and guides the herbs directly to the affected area in the fallopian tubes and uterus. The entire formula combines attack and tonification, with a reasonable combination of principal, assistant, and guiding herbs. Together, they achieve the effects of clearing heat and dampness, promoting blood circulation and removing blood stasis, nourishing yin and replenishing qi, and strengthening the spleen and kidneys.

[0024] This invention uses laying hens suffering from oviductitis as the research subject to investigate the therapeutic effect of the traditional Chinese medicine compound preparation of this invention on oviductitis in laying hens. Experimental results show that the traditional Chinese medicine compound preparation of this invention can exert a significant anti-inflammatory effect by regulating the level of cellular inflammatory factors, and can enhance the body's immune function by regulating the level of immune proteins. This can thereby reduce the decline in egg production caused by oviductitis, and decrease the mortality and defective egg rate caused by oviductitis. The therapeutic effect of the traditional Chinese medicine compound preparation of this invention on oviductitis in laying hens is significantly better than that of amoxicillin and Jinxin oral liquid, and it has great application potential in the treatment of oviductitis in laying hens. Attached Figure Description

[0025] Figure 1 The average daily egg production rate of each group before drug administration, within 7 days of drug administration, and within 7 days after the end of drug administration is statistically analyzed; Note: *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

[0026] Figure 2 The statistical results of the non-compliance egg rate for each group before drug administration, within 7 days of drug administration, and within 7 days after the end of drug administration; Note: *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

[0027] Figure 3The mortality rate of laying hens during the drug administration period is shown in Figure 1. Note: The same lowercase letter indicates no significant difference between groups (P>0.05); different lowercase letters indicate significant differences between groups (P<0.05). Detailed Implementation

[0028] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions of the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0029] Example 1

[0030] A traditional Chinese medicine compound preparation for treating oviductitis in laying hens, the traditional Chinese medicine compound preparation being made from the following traditional Chinese medicinal materials in parts by weight: 10 parts of Leonurus japonicus, 20 parts of Citrus aurantium, 10 parts of Euphorbia humifusa, 10 parts of Morus alba, 10 parts of Coleus sibiricum, 10 parts of Gynostemma pentaphyllum, 10 parts of Sophora flavescens, 10 parts of Solanum lyratum, 10 parts of Schisandra chinensis, and 5 parts of Glycyrrhiza uralensis.

[0031] The traditional Chinese medicine compound preparation is prepared according to the following method: weigh each traditional Chinese medicine raw material according to the above weight parts, wash and dry them, and then perform pulverization pretreatment. Then put the pretreated medicinal materials into an ultra-micro pulverizer for pulverization to 60-75μm. Mix them evenly to obtain the traditional Chinese medicine compound preparation.

[0032] The traditional Chinese medicine compound preparation can also be made into oral liquid, granules, or powder by using the above-mentioned weight proportions of traditional Chinese medicinal materials as raw materials and supplementing them with pharmaceutically acceptable excipients.

[0033] Example 2

[0034] The difference between this embodiment and Embodiment 1 is that the traditional Chinese medicine compound preparation is made from the following parts by weight of Chinese medicinal materials: 30 parts of Leonurus japonicus, 40 parts of Citrus aurantium, 30 parts of Euphorbia humifusa, 30 parts of Morus alba, 30 parts of Coix lacryma-jobi, 30 parts of Gynostemma pentaphyllum, 30 parts of Sophora flavescens, 30 parts of Solanum lyratum, 30 parts of Schisandra chinensis, and 20 parts of Glycyrrhiza uralensis.

[0035] Example 3

[0036] The difference between this embodiment and Embodiment 1 is that the traditional Chinese medicine compound preparation is made from the following parts by weight of Chinese medicinal materials: 22 parts of Leonurus japonicus, 36 parts of Citrus aurantium, 26 parts of Euphorbia humifusa, 22 parts of Morus alba, 28 parts of Coleus sibiricum, 28 parts of Gynostemma pentaphyllum, 24 parts of Sophora flavescens, 26 parts of Solanum lyratum, 22 parts of Schisandra chinensis, and 16 parts of Glycyrrhiza uralensis.

[0037] Example 4

[0038] The difference between this embodiment and Embodiment 1 is that the traditional Chinese medicine compound preparation is made from the following parts by weight of Chinese medicinal materials: 12 parts of Leonurus japonicus, 23 parts of Citrus aurantium, 14 parts of Euphorbia humifusa, 12 parts of Morus alba, 12 parts of Coix lacryma-jobi, 14 parts of Gynostemma pentaphyllum, 12 parts of Sophora flavescens, 12 parts of Solanum lyratum, 12 parts of Schisandra chinensis, and 8 parts of Glycyrrhiza uralensis.

[0039] Example 5

[0040] The difference between this embodiment and Embodiment 1 is that the traditional Chinese medicine compound preparation is made from the following parts by weight of Chinese medicinal materials: 10 parts of Leonurus japonicus, 25 parts of Citrus aurantium, 15 parts of Euphorbia humifusa, 10 parts of Morus alba, 15 parts of Coix lacryma-jobi, 15 parts of Gynostemma pentaphyllum, 10 parts of Sophora flavescens, 15 parts of Solanum lyratum, 10 parts of Schisandra chinensis, and 5 parts of Glycyrrhiza uralensis.

[0041] Example 6

[0042] The difference between this embodiment and Embodiment 1 is that the traditional Chinese medicine compound preparation is made from the following parts by weight of Chinese medicinal materials: 20 parts of Leonurus japonicus, 35 parts of Citrus aurantium, 25 parts of Euphorbia humifusa, 20 parts of Morus alba, 25 parts of Coix lacryma-jobi, 25 parts of Gynostemma pentaphyllum, 20 parts of Sophora flavescens, 25 parts of Solanum lyratum, 20 parts of Schisandra chinensis, and 15 parts of Glycyrrhiza uralensis.

[0043] Example 7

[0044] The difference between this embodiment and Embodiment 1 is that the traditional Chinese medicine compound preparation is made from the following parts by weight of Chinese medicinal materials: 15 parts of Leonurus japonicus, 30 parts of Citrus aurantium, 18 parts of Euphorbia humifusa, 15 parts of Morus alba, 18 parts of Coleus sibiricum, 18 parts of Gynostemma pentaphyllum, 15 parts of Sophora flavescens, 18 parts of Solanum lyratum, 15 parts of Schisandra chinensis, and 10 parts of Glycyrrhiza uralensis.

[0045] Example 8

[0046] The difference between this embodiment and Embodiment 1 is that the traditional Chinese medicine compound preparation is made from the following parts by weight of Chinese medicinal materials: 12 parts of Leonurus japonicus, 28 parts of Citrus aurantium, 20 parts of Euphorbia humifusa, 12 parts of Morus alba, 22 parts of Coix lacryma-jobi, 20 parts of Gynostemma pentaphyllum, 16 parts of Sophora flavescens, 18 parts of Solanum lyratum, 16 parts of Schisandra chinensis, and 12 parts of Glycyrrhiza uralensis.

[0047] Example 9

[0048] The difference between this embodiment and Embodiment 1 is that the traditional Chinese medicine compound preparation is made from the following parts by weight of Chinese medicinal materials: 16 parts of Leonurus japonicus, 32 parts of Citrus aurantium, 22 parts of Euphorbia humifusa, 18 parts of Morus alba, 20 parts of Coix lacryma-jobi, 22 parts of Gynostemma pentaphyllum, 14 parts of Sophora flavescens, 21 parts of Solanum lyratum, 18 parts of Schisandra chinensis, and 9 parts of Glycyrrhiza uralensis.

[0049] Test case

[0050] 1. Materials and Methods

[0051] 1.1 Laboratory Animals

[0052] 375 Hy-Line Grey laying hens with oviductitis were selected from the farm. The selection criteria for sick laying hens were: similar weight, 400-420 days old, no eggs for 2-3 consecutive days, and eggs with broken shells, sandy shells, dirty eggs (eggshells with blood, feces or mucus), and deformed eggs. Three laying hens were randomly selected for dissection and obvious oviduct lesions were found.

[0053] 1.2 Experimental Drugs

[0054] The traditional Chinese medicine compound preparation of this invention is prepared by weighing the following herbs according to their respective weights: 16g of Leonurus japonicus, 32g of Citrus aurantium, 22g of Euphorbia humifusa, 18g of Morus alba, 20g of Coix lacryma-jobi, 22g of Gynostemma pentaphyllum, 14g of Sophora flavescens, 21g of Solanum lyratum, 18g of Schisandra chinensis, and 9g of Glycyrrhiza uralensis. After washing and drying, the herbs are pulverized in an ultra-micro pulverizer to a particle size of 60-75μm and then mixed evenly.

[0055] 30% amoxicillin soluble powder; Shengtai'er Jinxin oral solution.

[0056] 1.3 Grouping and Processing

[0057] A single-factor completely randomized design was used to randomly divide diseased laying hens into 5 groups of 75 birds each: a model group, a western medicine control group, a traditional Chinese medicine control group, a low-dose group of the traditional Chinese medicine compound preparation of this invention (hereinafter referred to as the low-dose group), and a high-dose group of the traditional Chinese medicine compound preparation of this invention (hereinafter referred to as the high-dose group). An additional 75 healthy Hy-Line Grey laying hens aged 400-420 days were selected as the normal control group. The administration methods and dosages for each group are shown in Table 1.

[0058] Table 1 Grouping and Processing

[0059]

[0060] All groups were fed a basal diet, and all feeds were powdered.

[0061] 1.4 Feeding and Management

[0062] During the experiment, the laying hens were cage-raised, with each replicate in each group in a separate cage. The light exposure time was 16 hours, the indoor temperature was (25.5±2.5)℃, and the relative humidity was (75±5)%. They were artificially fed, and the drug administration period was 7 days. After the drug was stopped, the observation continued for another 7 days. The flock's condition and egg production were observed daily.

[0063] 1.5 Measurement Indicators and Methods

[0064] 1.5.1 Egg production performance

[0065] 1.5.1.1 Daily egg production rate

[0066] Egg production in each group was recorded at the same time each day for 3 days before administration, 7 days after administration, and 7 days after administration, and the average daily egg production rate of each group was calculated for different time periods.

[0067] Average daily egg production rate (%) = Total number of eggs produced / (Number of chickens × Number of days in the trial) × 100%

[0068] 1.5.1.2 Rate of substandard eggs

[0069] The number of duplicate non-compliant eggs (blood eggs, dirty eggs, broken eggs, soft eggs, sandy eggs, and deformed eggs) in each group was recorded at the same time every day for 3 days before administration, 7 days after administration, and 7 days after administration. The non-compliant egg rate for each duplicate on that day was calculated.

[0070] Failure rate (%) = (Number of defective eggs / Total number of eggs) × 100%

[0071] 1.5.1.3 Death Rate

[0072] During the administration period, the number of chicken deaths per replicate was recorded, and the mortality rate was calculated.

[0073] Mortality rate (%) = (Number of culled hens / Number of laying hens admitted) × 100%

[0074] 1.5.2 Immune indicators

[0075] Twelve hours after the administration of the drug, five laying hens were randomly selected from each replicate of each group to collect blood from the wing vein. The blood was centrifuged, the supernatant was collected, and the serum levels of TNF-α, IFN-γ, IL-6, IL-8, IL-10, IgM, and IgG were detected using an ELISA kit.

[0076] 1.6 Statistical Analysis

[0077] Data were processed using SPSS 20.0 one-way ANOVE analysis (Duncan'D). Data are expressed as mean ± standard deviation, and P < 0.05 was considered statistically significant.

[0078] 2 Results

[0079] 2.1 Average daily egg production rate of each group of laying hens

[0080] The results of the average daily egg production rate of each group of laying hens are as follows: Figure 1As shown in the figure. Before administration, compared with the control group, the egg production rate of each diseased laying hen group was significantly reduced, with highly significant differences (P<0.0001). During the administration period, the egg production rate of the model group continued to decline. Compared with the model group, the average daily egg production rate of each administration group was significantly increased (P<0.0001). Among them, the average daily egg production rate of the laying hens in the low-dose group of the traditional Chinese medicine of this invention was significantly higher than that of the western medicine control group (P<0.01). Within 7 days after the end of administration, the egg production rate of the laying hens in the model group continued to decline. Compared with the model group, the average daily egg production rate of each administration group was significantly increased (P<0.0001). Among them, the average daily egg production rate of the laying hens in the low-dose group of the traditional Chinese medicine of this invention was significantly higher than that of the western medicine control group and the traditional Chinese medicine control group (P<0.001, P<0.05).

[0081] 2.2 Rate of unqualified eggs in each group of laying hens

[0082] The results of the non-compliance egg rate of each group of laying hens are as follows: Figure 2 As shown in the figure. Before administration, compared with the control group, the rate of substandard eggs in each diseased laying hen group was significantly increased, with highly significant differences (P<0.0001). During the administration period, the rate of substandard eggs in the model group continued to increase. Compared with the model group, the rate of substandard eggs in each administered group was significantly reduced (P<0.0001). Among them, the rate of substandard eggs in the low-dose group of the traditional Chinese medicine of this invention was significantly lower than that in the Western medicine control group and the traditional Chinese medicine control group (P<0.01, P<0.05). Within 7 days after the end of administration, the rate of substandard eggs in the model group continued to increase. Compared with the model group, the rate of substandard eggs in each administered group was significantly reduced (P<0.0001). Among them, the rate of substandard eggs in the low-dose group of the traditional Chinese medicine of this invention was significantly lower than that in the Western medicine control group and the traditional Chinese medicine control group (P<0.001, P<0.01).

[0083] 2.3 Mortality rate of laying hens in each group

[0084] The mortality rates of laying hens during the drug administration period for each group are as follows: Figure 3 As shown. Compared with the blank group, the mortality rate of laying hens in the model group was significantly increased (P<0.05). Compared with the model group, the mortality rate of laying hens in each treatment group was significantly reduced (P<0.05); among them, the mortality rate of laying hens in the low-dose and high-dose groups of the traditional Chinese medicine of this invention was significantly lower than that in the western medicine control group (P<0.05), slightly lower than that in the traditional Chinese medicine control group, and comparable to that in the blank group, with no statistically significant difference (P>0.05).

[0085] 2.4 Serum Immune Indicators of Laying Hens in Each Group

[0086] The results of serum inflammatory factor indicators in laying hens of each group are shown in Table 2. Compared with the blank group, the levels of inflammatory factors such as IL-6, IL-8, TNF-α, and IFN-γ in the serum of laying hens in the model group were significantly increased (P<0.05). Compared with the model group, the levels of inflammatory factors such as IL-6, IL-8, TNF-α, and IFN-γ in the serum of laying hens in each treatment group were significantly decreased to varying degrees (P<0.05); among them, the levels of inflammatory factors such as IL-6, IL-8, TNF-α, and IFN-γ in the serum of laying hens in the high-dose group of the traditional Chinese medicine of this invention were significantly lower than those in the western medicine control group or the traditional Chinese medicine control group to varying degrees (P<0.05).

[0087] The results of serum immunoglobulin levels in laying hens in each group are shown in Table 3. Compared with the control group, the levels of immunoglobulins IgM and IgG in the serum of laying hens in the model group were significantly increased (P<0.05). Compared with the model group, the levels of immunoglobulins IgM and IgG in the serum of laying hens in each treatment group were significantly decreased (P<0.05). Among them, the levels of immunoglobulins IgM and IgG in the serum of laying hens in the low-dose group and high-dose group of the traditional Chinese medicine of this invention were comparable to those in the control group, with no statistically significant difference (P>0.05).

[0088] Table 2 Serum inflammatory factor indices of laying hens in each group

[0089]

[0090] Note that in the same column, the same lowercase letter under the superscript indicates no significant difference between groups (P>0.05); different lowercase letters under the superscript indicate significant differences between groups (P<0.05).

[0091] Table 3. Serum immunoglobulin levels in laying hens of each group

[0092]

[0093] Note that in the same column, the same lowercase letter under the superscript indicates no significant difference between groups (P>0.05); different lowercase letters under the superscript indicate significant differences between groups (P<0.05).

[0094] 3. Conclusion

[0095] Oviductitis significantly reduces egg production in laying hens, increases the rate of defective eggs, and raises mortality rates, severely impacting hen productivity and farmers' economic benefits. This experiment focused on laying hens with oviductitis to investigate the therapeutic effect of the traditional Chinese medicine compound preparation of this invention on oviductitis. The results showed that the traditional Chinese medicine compound preparation of this invention effectively improved egg production in hens with oviductitis, significantly reduced the proportion of defective eggs such as bloody eggs, dirty eggs, broken eggs, soft-shelled eggs, sandy eggs, and deformed eggs, and maintained a longer therapeutic effect, facilitating the recovery of the hens to productive status. It also demonstrated a significant advantage in reducing mortality rates in affected hens. The therapeutic effects on hens with oviductitis were significantly superior to amoxicillin and Jinxin oral liquid.

[0096] Studies have shown that cellular inflammatory factors play an important role in oviductitis in laying hens. IL-6, IL-8, and TNF-α are important pro-inflammatory cytokines in immune regulation and inflammation control, while IFN-γ is a key regulator of macrophage activation and can promote oviductal inflammatory damage. In the above results, the serum levels of IL-6, IL-8, TNF-α, and IFN-γ in diseased laying hens were significantly increased compared to healthy laying hens, consistent with previous reports. After drug treatment, all treatment groups significantly reduced the levels of pro-inflammatory factors IL-6, IL-8, TNF-α, and IFN-γ. The high-dose group of the traditional Chinese medicine in this invention showed the best anti-inflammatory effect, indicating that the compound preparation of the traditional Chinese medicine in this invention can achieve a therapeutic effect on oviductitis in laying hens by regulating the levels of inflammatory factors.

[0097] The oviduct mucosa of hens is sensitive to pathogens, often causing mucosal inflammation, leading to deterioration of the host animal's health, reduced egg production, and bacterial contamination of eggs. We further evaluated the effect of the traditional Chinese medicine compound preparation of this invention in treating oviductitis in laying hens by detecting immune-related indicators in serum. IgM and IgG are important immunoglobulins in poultry; inflammation leads to elevated immunoglobulin levels. In the above results, both IgM and IgG levels in the serum of diseased laying hens were significantly increased, indicating that the body produced a corresponding immune defense against inflammatory stimuli. After drug treatment, the levels of IgM and IgG in the serum of diseased laying hens in all treatment groups were significantly reduced. Specifically, the levels of IgM and IgG in the serum of laying hens in the low-dose and high-dose groups of the traditional Chinese medicine preparation of this invention tended to return to normal levels, showing no significant difference compared to healthy laying hens. This indicates that the traditional Chinese medicine compound preparation of this invention can regulate serum immune protein levels, improve the body's immune performance, and further enhance the body's disease resistance and recovery ability.

[0098] In summary, the traditional Chinese medicine compound preparation of this invention can exert a significant anti-inflammatory effect by regulating the level of cellular inflammatory factors, and enhance the body's immune function by regulating the level of immune proteins. This can thereby reduce the decline in egg production caused by oviductitis in laying hens, and decrease the mortality and defective egg rates caused by oviductitis. The therapeutic effect of this traditional Chinese medicine compound preparation on oviductitis in laying hens is significantly better than that of amoxicillin and Jinxin oral liquid, and it has great application potential in the treatment of oviductitis in laying hens.

[0099] The above embodiments are only used to illustrate the technical solutions of the present invention, and are not intended to limit it. Although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some of the technical features. Such modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. A traditional Chinese medicine compound preparation for treating oviductitis in laying hens, characterized in that, The traditional Chinese medicine compound preparation is made from the following Chinese medicinal materials in parts by weight: 10-30 parts of Leonurus japonicus, 20-40 parts of Citrus aurantium, 10-30 parts of Euphorbia humifusa, 10-30 parts of Morus alba, 10-30 parts of Coix lacryma-jobi, 10-30 parts of Gynostemma pentaphyllum, 10-30 parts of Sophora flavescens, 10-30 parts of Solanum lyratum, 10-30 parts of Schisandra chinensis, and 5-20 parts of Glycyrrhiza uralensis.

2. The traditional Chinese medicine compound preparation for treating oviductitis in laying hens as described in claim 1, characterized in that, The traditional Chinese medicine compound preparation is made from the following Chinese medicinal materials in parts by weight: 10-20 parts of Leonurus japonicus, 25-35 parts of Citrus aurantium, 15-25 parts of Euphorbia humifusa, 10-20 parts of Morus alba, 15-25 parts of Eupatorium fortunei, 15-25 parts of Gynostemma pentaphyllum, 10-20 parts of Sophora flavescens, 15-25 parts of Solanum lyratum, 10-20 parts of Schisandra chinensis, and 5-15 parts of Glycyrrhiza uralensis.

3. A traditional Chinese medicine compound preparation for treating oviductitis in laying hens as described in claim 1, characterized in that, The traditional Chinese medicine compound preparation is made from the following Chinese medicinal materials in parts by weight: 16 parts of Leonurus japonicus, 32 parts of Citrus aurantium, 22 parts of Euphorbia humifusa, 18 parts of Morus alba, 20 parts of Coix lacryma-jobi, 22 parts of Gynostemma pentaphyllum, 14 parts of Sophora flavescens, 21 parts of Solanum lyratum, 18 parts of Schisandra chinensis, and 9 parts of Glycyrrhiza uralensis.

4. A traditional Chinese medicine compound preparation for treating oviductitis in laying hens as described in any one of claims 1 to 3, characterized in that, The traditional Chinese medicine compound preparation uses the stated weight proportions of Chinese medicinal materials as raw materials, supplemented with pharmaceutically acceptable excipients to produce oral liquids, granules, powders, or concentrates.

5. A method for preparing a traditional Chinese medicine compound preparation for treating oviductitis in laying hens as described in any one of claims 1 to 3, characterized in that, The preparation method of the traditional Chinese medicine compound preparation is as follows: weigh each traditional Chinese medicine raw material according to the above weight parts, wash and dry them, perform pulverization pretreatment, then put the pretreated medicinal materials into an ultra-micro pulverizer for pulverization to 60-75μm, and mix them evenly to obtain the traditional Chinese medicine compound preparation.

Images